FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Ocuphire Pharma, Inc (NASDAQ: OCUP) Surges After VEGA-1 Phase 2 Trial Met Study Endpoints In Presbyopic Patients”
Ocuphire Pharma, Inc. (NASDAQ: OCUP) surged over 40% in premarket trading after the company’s VEGA-1 Phase 2 Trial in Presbyopia Met its Primary and Secondary Endpoints.
Key secondary endpoints on visual acuity and pupil diameter showed statistical significance and the Company now plans to advance into Phase 3 registration trials.
Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® (0.75% phentolamine ophthalmic solution) Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal of pharmacologically-induced mydriasis (RM), and presbyopia, and has been studied in 9 clinical trials including the recently completed Phase 3 trial in RM and Phase 2 trial in presbyopia.
For more information, please visit: Ocuphire Pharma, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.